These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38215555)

  • 1. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
    Didi I; Alliot JM; Dumas PY; Vergez F; Tavitian S; Largeaud L; Bidet A; Rieu JB; Luquet I; Lechevalier N; Delabesse E; Sarry A; De Grande AC; Bérard E; Pigneux A; Récher C; Simoncini D; Bertoli S
    Leuk Res; 2024 Jan; 136():107437. PubMed ID: 38215555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
    Gadaud N; Leroy H; Bérard E; Tavitian S; Leguay T; Dimicoli-Salazar S; Rieu JB; Luquet I; Largeaud L; Bidet A; Delabesse E; Klein E; Sarry A; de Grande AC; Bories P; Pigneux A; Récher C; Dumas PY; Bertoli S
    Leuk Lymphoma; 2022 Jun; 63(6):1398-1406. PubMed ID: 35634787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
    Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
    Pleyer L; Burgstaller S; Girschikofsky M; Linkesch W; Stauder R; Pfeilstocker M; Schreder M; Tinchon C; Sliwa T; Lang A; Sperr WR; Krippl P; Geissler D; Voskova D; Schlick K; Thaler J; Machherndl-Spandl S; Theiler G; Eckmüllner O; Greil R
    Ann Hematol; 2014 Nov; 93(11):1825-38. PubMed ID: 24951123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
    Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
    Falantes J; Pleyer L; Thépot S; Almeida AM; Maurillo L; Martínez-Robles V; Stauder R; Itzykson R; Pinto R; Venditti A; Bargay J; Burgstaller S; Martínez MP; Seegers V; Cortesão E; Foncillas MÁ; Gardin C; Montesinos P; Musto P; Fenaux P; Greil R; Sanz MA; Ramos F;
    Leuk Lymphoma; 2018 May; 59(5):1113-1120. PubMed ID: 28838276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
    Gupta N; Miller A; Gandhi S; Ford LA; Vigil CE; Griffiths EA; Thompson JE; Wetzler M; Wang ES
    Am J Hematol; 2015 Jul; 90(7):639-46. PubMed ID: 25808347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
    Pleyer L; Stauder R; Burgstaller S; Schreder M; Tinchon C; Pfeilstocker M; Steinkirchner S; Melchardt T; Mitrovic M; Girschikofsky M; Lang A; Krippl P; Sliwa T; Egle A; Linkesch W; Voskova D; Angermann H; Greil R
    J Hematol Oncol; 2013 Apr; 6():32. PubMed ID: 23627920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
    Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
    Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
    Cherry EM; Abbott D; Amaya M; McMahon C; Schwartz M; Rosser J; Sato A; Schowinsky J; Inguva A; Minhajuddin M; Pei S; Stevens B; Winters A; Jordan CT; Smith C; Gutman JA; Pollyea DA
    Blood Adv; 2021 Dec; 5(24):5565-5573. PubMed ID: 34610123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.
    Arana Rosainz MJ; Nguyen N; Wahed A; Lelenwa LC; Aakash N; Schaefer K; Rios A; Kanaan Z; Chen L
    Int J Lab Hematol; 2021 Apr; 43(2):218-226. PubMed ID: 33099879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
    Thépot S; Itzykson R; Seegers V; Recher C; Raffoux E; Quesnel B; Delaunay J; Cluzeau T; Marfaing Koka A; Stamatoullas A; Chaury MP; Dartigeas C; Cheze S; Banos A; Morel P; Plantier I; Taksin AL; Marolleau JP; Pautas C; Thomas X; Isnard F; Beve B; Chait Y; Guerci A; Vey N; Dreyfus F; Ades L; Ifrah N; Dombret H; Fenaux P; Gardin C;
    Am J Hematol; 2014 Apr; 89(4):410-6. PubMed ID: 24375487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.
    Tombak A; Uçar MA; Akdeniz A; Tiftik EN; Gören Şahin D; Akay OM; Yıldırım M; Nevruz O; Kis C; Gürkan E; Solmaz ŞM; Özcan MA; Yıldırım R; Berber İ; Erkurt MA; Fıratlı Tuğlular T; Tarkun P; Yavaşoğlu İ; Doğu MH; Sarı İ; Merter M; Özcan M; Yıldızhan E; Kaynar L; Mehtap Ö; Uysal A; Şahin F; Salim O; Sungur MA
    Turk J Haematol; 2016 Dec; 33(4):273-280. PubMed ID: 27095141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
    Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
    Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
    Gemuenden C; Benz R; Senn O; Goede JS; Manz MG; Gerber B
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.